Compare Stocks: MLYS, RDY, CRNX, and BLTE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$169.44 -2.1%	$162.28	$64.80 ▼ $200.00	$6.97B	-1.23	201,046 shs	151,849 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.32	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
MLYS Mineralys Therapeutics	$28.91 -0.1%	$27.21	$22.30 ▼ $47.65	$2.56B	0.68	1.07 million shs	1.78 million shs
RDY Dr. Reddy's Laboratories	$11.54 -3.1%	$12.24	$11.36 ▼ $15.67	$9.94B	0.28	2.49 million shs	4.23 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-0.45%	-10.65%	+6.27%	+25.19%	+148.99%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+0.30%	+142.71%	+149.85%
MLYS Mineralys Therapeutics	+2.66%	+2.62%	+12.91%	+20.68%	-21.97%
RDY Dr. Reddy's Laboratories	-0.01%	-0.54%	-3.17%	-10.52%	-18.74%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLTE Belite Bio	$169.44 -2.1%	$162.28	$64.80 ▼ $200.00	$6.97B	-1.23	201,046 shs	151,849 shs
CRNX Crinetics Pharmaceuticals	$84.95	$84.32	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
MLYS Mineralys Therapeutics	$28.91 -0.1%	$27.21	$22.30 ▼ $47.65	$2.56B	0.68	1.07 million shs	1.78 million shs
RDY Dr. Reddy's Laboratories	$11.54 -3.1%	$12.24	$11.36 ▼ $15.67	$9.94B	0.28	2.49 million shs	4.23 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLTE Belite Bio	-0.45%	-10.65%	+6.27%	+25.19%	+148.99%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+0.30%	+142.71%	+149.85%
MLYS Mineralys Therapeutics	+2.66%	+2.62%	+12.91%	+20.68%	-21.97%
RDY Dr. Reddy's Laboratories	-0.01%	-0.54%	-3.17%	-10.52%	-18.74%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLTE Belite Bio	2.64	Moderate Buy	$218.73	29.09% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.65% Downside
MLYS Mineralys Therapeutics	2.50	Moderate Buy	$48.80	68.80% Upside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A

Current Analyst Ratings Breakdown

Latest MLYS, RDY, CRNX, and BLTE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	MLYS Mineralys Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
9/9/2026	BLTE Belite Bio	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$220.00 ➝ $234.00
9/9/2026	BLTE Belite Bio	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold
9/8/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$245.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/4/2026	BLTE Belite Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$303.00
9/3/2026	BLTE Belite Bio	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/3/2026	BLTE Belite Bio	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$214.00 ➝ $245.00
9/2/2026	CRNX Crinetics Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/18/2026	BLTE Belite Bio	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/14/2026	BLTE Belite Bio	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$201.00 ➝ $206.00

(Data available from 9/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLTE Belite Bio	N/A	N/A	N/A	N/A	$20.54 per share	N/A
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$8.17 per share	N/A
RDY Dr. Reddy's Laboratories	$3.58B	2.69	$0.82 per share	14.06	$4.86 per share	2.37

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLTE Belite Bio	-$77.61M	-$2.73	N/A	186.20	N/A	N/A	-11.84%	-11.62%	11/9/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
MLYS Mineralys Therapeutics	-$154.65M	-$4.24	N/A	N/A	N/A	N/A	-57.97%	-54.15%	11/9/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	26.23	20.25	2.48	10.15%	9.49%	6.32%	10/23/2026 (Estimated)

Latest MLYS, RDY, CRNX, and BLTE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	BLTE Belite Bio	-$0.73	-$0.54	+$0.19	-$0.70	N/A	N/A
8/12/2026	Q2 2026	MLYS Mineralys Therapeutics	-$0.5486	-$2.85	-$2.3014	-$2.85	N/A	N/A
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million
6/30/2026	Q2 2026	BLTE Belite Bio	N/A	-$0.54	N/A	-$0.70	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLTE Belite Bio	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.52%	+6.96%	13.64%	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLTE Belite Bio	N/A	33.56	33.56
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
MLYS Mineralys Therapeutics	0.18	34.46	34.46
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLTE Belite Bio	0.53%
CRNX Crinetics Pharmaceuticals	98.51%
MLYS Mineralys Therapeutics	84.46%
RDY Dr. Reddy's Laboratories	3.85%

Insider Ownership

Company	Insider Ownership
BLTE Belite Bio	13.29%
CRNX Crinetics Pharmaceuticals	3.80%
MLYS Mineralys Therapeutics	18.94%
RDY Dr. Reddy's Laboratories	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLTE Belite Bio	41	40.27 million	34.92 million	Not Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
MLYS Mineralys Therapeutics	76	88.41 million	71.66 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.98 million	Optionable

MLYS, RDY, CRNX, and BLTE Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 15 at 5:24 PM | globenewswire.com

Wellington Management Group LLP Cuts Position in Dr. Reddy's Laboratories Ltd $RDY

September 12 at 4:23 AM | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 8, 2026 | globenewswire.com

Nykredit A S Takes $2 Million Position in Dr. Reddy's Laboratories Ltd $RDY

September 8, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 3, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

September 1, 2026 | globenewswire.com

Dr. Reddy's Laboratories (NYSE:RDY) Upgraded to Hold at Wall Street Zen

August 29, 2026 | marketbeat.com

Dr. Reddy's Laboratories Ltd $RDY Shares Sold by Bank of America Corp DE

August 28, 2026 | marketbeat.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

August 27, 2026 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Dr. Reddy's Laboratories Limited - RDY

August 25, 2026 | globenewswire.com

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced - Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 19, 2026 | tmcnet.com

Securities Fraud Investigation Into Dr. Reddy's Laboratories (RDY) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

August 19, 2026 | businesswire.com

RDY SHAREHOLDER ALERT: Dr. Reddy's Laboratories Investors Encouraged to Contact Kirby McInerney LLP About Potential Securities Laws Violations

August 13, 2026 | businesswire.com

Dr. Reddy's Laboratories Ltd. Sponsored ADR

August 12, 2026 | cnn.com

Dr. Reddy's Laboratories Launches Sugammadex Injection Single-Dose Vials in US

August 5, 2026 | finance.yahoo.com

DR. REDDY'S LABORATORIES INVESTOR ALERT: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud

August 5, 2026 | globenewswire.com

Dr. Reddy’s Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of ...

August 4, 2026 | finance.yahoo.com

Dr. Reddy's Announces the First-to-Market Launch of Sugammadex Injection 200 mg/2 mL (100 mg/mL) and 500 mg/5 mL (100 mg/mL) Single-Dose Vials, a Generic Equivalent of Bridion®, in the United States

August 4, 2026 | businesswire.com

Dr. Reddy's Laboratories (RDY) Securities Investigation Notice - Levi & Korsinsky

July 31, 2026 | prnewswire.com

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving Dr. Reddy's Laboratories (RDY)

July 29, 2026 | globenewswire.com

Dr Reddys Laboratories Ltd (RDY)

July 28, 2026 | insidermonkey.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS, RDY, CRNX, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

$169.44 -3.56 (-2.06%)

Closing price 04:00 PM Eastern

Extended Trading

$169.53 +0.09 (+0.05%)

As of 07:30 PM Eastern

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. The company's lead product candidate is LBS-008 (Tinlarebant), an orally administered once-a-day tablet for maintaining the health and integrity of retinal tissues in autosomal recessive Stargardt disease and geographic atrophy patients. It is also developing LBS-009, an anti-retinol binding protein 4 oral therapy that is in the preclinical development phase targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc is a subsidiary of Lin Bioscience International Ltd.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Mineralys Therapeutics NASDAQ:MLYS

$28.91 -0.04 (-0.14%)

Closing price 04:00 PM Eastern

Extended Trading

$28.90 -0.02 (-0.05%)

As of 07:30 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

Dr. Reddy's Laboratories NYSE:RDY

$11.54 -0.37 (-3.11%)

Closing price 03:59 PM Eastern

Extended Trading

$11.69 +0.15 (+1.30%)

As of 07:54 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MLYS, RDY, CRNX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MLYS, RDY, CRNX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MLYS, RDY, CRNX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS, RDY, CRNX, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Mineralys Therapeutics NASDAQ:MLYS

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MLYS, RDY, CRNX, and BLTE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MLYS, RDY, CRNX, and BLTE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MLYS, RDY, CRNX, and BLTE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MLYS, RDY, CRNX, and BLTE Company Descriptions

Belite Bio NASDAQ:BLTE

Crinetics Pharmaceuticals NASDAQ:CRNX

Mineralys Therapeutics NASDAQ:MLYS

Dr. Reddy's Laboratories NYSE:RDY

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools